ResMed's stock surged 6.36% during pre-market trading on Friday, indicating strong investor interest ahead of the regular session.
The significant price jump appears to be driven by positive analyst actions, with both RBC and Jefferies raising their price targets for the medical device company. RBC increased its target to $314 from $311, while Jefferies raised its target to $290 from $285.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.